{"id":"NCT02151851","sponsor":"UCB Pharma SA, Belgium","briefTitle":"A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis","officialTitle":"A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel Group, Randomized 24-week Study to Evaluate the Safety and Efficacy of Certolizumab Pegol (CZP) as Additional Medication to Methotrexate in Chinese Subjects With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-07","primaryCompletion":"2016-06","completion":"2016-06","firstPosted":"2014-05-30","resultsPosted":"2018-03-20","lastUpdate":"2018-06-28"},"enrollment":430,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"BIOLOGICAL","name":"Certolizumab Pegol","otherNames":["Cimzia"]},{"type":"DRUG","name":"Methotrexate","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Certolizumab Pegol + Methotrexate","type":"EXPERIMENTAL"},{"label":"Placebo + Methotrexate","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate the safety \\& efficacy of Certolizumab Pegol (CZP) as additional medication to Methotrexate (MTX) in Chinese subjects with Rheumatoid Arthritis. 400 patients will be randomized to receive either CZP + MTX or placebo + MTX. Anticipated time in the study is about 32 weeks.","primaryOutcome":{"measure":"Percentage of Subjects Meeting the American College of Rheumatology 20 % Response Criteria (ACR20) at Week 24","timeFrame":"Week 24","effectByArm":[{"arm":"Placebo + Methotrexate (FAS)","deltaMin":23.9,"sd":null},{"arm":"Certolizumab Pegol + Methotrexate (FAS)","deltaMin":54.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":29},"locations":{"siteCount":30,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":113},"commonTop":["Upper respiratory tract infection","Latent tuberculosis","Alanine aminotransferase increased","Liver function test abnormal","Anaemia"]}}